The Patent Finder

Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions

Musc Foundation for Research Development

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 3 of these applications claim priority to application PCT/US2008/051168, filed Jan 16, 2008. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 8,735,365Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy
In force
 · Medium confidence
Musc Foundation for Research DevelopmentIn force
Medium confidence
US 7,964,577Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy
In force
 · High confidence
Phigenix, Inc.In force
High confidence
US 8,623,617Detecting PAX2 for the Diagnosis of Breast Cancer
In force (reinstated)
 · Medium confidence
Musc Foundation for Research DevelopmentIn force (reinstated)
Medium confidence
US 8,722,367Detecting PAX2 for the Diagnosis of Breast Cancer
In force
 · Medium confidence
Musc Foundation for Research DevelopmentIn force
Medium confidence
US 8,088,603Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions
In force
 · High confidence
Musc Foundation for Research DevelopmentIn force
High confidence
US 8,318,692Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy
Lapsed Nov 27, 2024 on the fee record
High confidence
Musc Foundation for Research DevelopmentLapsed Nov 27, 2024 on the fee record
High confidence
US 8,431,546Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy
Lapsed Apr 30, 2025 on the fee record
High confidence
Musc Foundation for Research DevelopmentLapsed Apr 30, 2025 on the fee record
High confidence
US 8,445,444Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions
Lapsed May 21, 2025 on the fee record
Medium confidence
Musc Foundation for Research DevelopmentLapsed May 21, 2025 on the fee record
Medium confidence
US 8,461,101Targeting PAX2 for the Treatment of Breast Cancer
Lapsed Jun 11, 2025 on the fee record
High confidence
Musc Foundation for Research DevelopmentLapsed Jun 11, 2025 on the fee record
High confidence
US 8,461,126Targeting EN2, PAX2, And/Or DEFB1 for Treatment of Prostate Conditions
Lapsed Jun 11, 2025 on the fee record
High confidence
Musc Foundation for Research DevelopmentLapsed Jun 11, 2025 on the fee record
High confidence
16 more patents in this group · Pro
10 of 26 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 26, including 10 expired and 4 expiring within the 18 months from Nov 18, 2026.
Upgrade to Pro
4 of these are in force and held by Musc Foundation for Research Development.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited